Bloomberg BNA's Health IT Law & Industry Report brings you concise, comprehensive, and timely news and analysis of the regulatory, legal, and compliance issues surrounding our nation’s...
The Office of the National Coordinator for Health Information Technology's workgroup on “meaningful use” began April 5 incorporating public comments into its proposed criteria for Stage 2 of the electronic health records incentive program.
For many of the meaningful use objectives, the workgroup aimed to clarify or define the intent of the objective for the broader health care community.
ONC received more than 400 public comment submissions on the workgroup's proposed criteria for Stage 2 of the Medicare and Medicaid EHR incentive programs.
For objectives related to improving the quality, safety, and efficiency of health care, such as computerized physician order entry (CPOE), drug interaction, and electronic prescribing, the proposed criteria remained predominantly unchanged.
However, for clinical decision support, the workgroup agreed that the criteria for certification should be more specific. Clinical decision support (CDS) capabilities should include:
• providing a method of displaying to the provider the source or citation of the CDS;
• allowing rules to be configured to enable decision support based on patients' context, such as clinic visit or admission status;
• responding to information in patient charts about the patients' problems, allergies, medications, and vital signs; and
• integrating CDS with other EHR capabilities.
The meaningful use workgroup is aiming to make final recommendations on Stage 2 objectives, criteria, and implementation specifications in June. CMS is expected to publish the proposed Stage 2 meaningful use rule by the end of calendar year 2011, and publish the final rule by mid-2012.
For many objectives related to improving patient engagement in care, such as clinical summaries, electronic access to health information, and discharge summaries, the easiest way to satisfy all of these requirements could be through making the data and information available to patients via a patient portal, Paul Tang, chair of the meaningful use workgroup and Palo Alto Medical Foundation chief medical information officer, said.
While the hospital portal requirement would be optional for achieving Stage 2 of meaningful use, by Stage 3 of the incentive program meaningful use it should become mandatory, workgroup members agreed.
Other forms of communication between patients and providers, such as secure messaging, would be mandatory, however, Tang said.
More complex objectives, such as engaging in bidirectional health information exchange and medication reconciliation, will require further discussions, workgroup members said.
Workgroup members voted to explore recommendations made in comment letters to change the Stage 2 reporting period requirements from a full year to 90 days. This change would give implementers of health IT systems an additional nine months to prepare for Stage 2 of meaningful use, Tang said.
Some workgroup members expressed concerns with making the timing change, and said the workgroup should first analyze how such a change would affect the incentive program before making an official recommendation on the matter.
Charlene Underwood, workgroup member and director of government and industry affairs for Siemens Medical Solutions, said the additional nine months of preparation may not be enough to make the changes necessary for Stage 2. Underwood did, however, support looking into reducing the time of the reporting period.
Several workgroup members urged that the advisory group wait until there is more evidence on how the first phase of the meaningful use program is working in hospitals and physician practices. “We really need to see how Stage 1 is being implemented in the field,” Deven McGraw, workgroup member and director of the Center for Democracy and Technology's Health Privacy Project, said.
Additional information and materials from the meeting and workgroup are available at http://healthit.hhs.gov/FACAs by clicking on the April 5 entry for the meaningful use workgroup.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)